вторник, 20 сентября 2011 г.

In Pediatric Genetic Neurological Disease Niemann-Pick Type C, Researchers Report Breakthrough

A paper announcing a breakthrough discovery in the fight against Niemann-Pick Type C, coauthored by Olaf Wiest and Paul Helquist of the University of Notre Dame's Department Chemistry & Biochemistry and Frederick Maxfield, Chair of Biochemistry at Cornell University Weill College of Medicine, appears in the Proceedings of the National Academy of Sciences this week. The paper shows how use of a histone deacetylase inhibitor correct the damage done by the genetic disorder and allowed once-diseased cells to function normally.



Niemann-PickType C (NPC) involves a genetic flaw that keeps cells from using lipids appropriately and leaves the lipids trapped in the cell. Brain cells are especially impacted, and destruction of brain cells typically kills victims by their teen years and there is currently no treatment available in the U.S. NPC is an inherited cholesterol metabolism disorder that strikes one in every 150,000 children. It has been referred to by the National Institutes of Health as "childhood Alzheimer's" because of similarities in the brains of NPC and Alzheimer's disease patients.



Three of the four grandchildren of former Notre Dame head football coach Ara Parseghian died of NPC, and the University has been involved in research on the disorder for years. Last year, it formally united with the Parseghian Foundation, which sponsored this work.



Last summer, Notre Dame College of Science Dean Gregory Crawford and his wife Renate bicycled 2,300 miles from Tucson to Notre Dame to raise awareness of the newly strengthened partnership with the Parseghian Foundation. Notre Dame's Center for Rare and Neglected Diseases works to develop therapies and outreach efforts for people suffering from conditions, like NPC, that have bee3n largely ignored by pharmaceutical companies.



A team of led by Wiest and Helquist at Notre Dame and Maxfield at Cornell, uncovered evidence that histone deacetylase inhibitors correct NPC's genetic flaw. Detailed images obtained at Cornell by Maxfield's group gave vivid evidence of the drug's effectiveness, showing how NPC cells became indistinguishable from normal human cells after treatment with the drug. The histine deacetylase inhibitors have a wide range of potential uses, from rare diseases, the focus at Notre Dame, to several forms of cancer, including leukemia, where they can increase the number of bone marrow cells.



Several of the compounds studied are shown to be safe in advanced clinical studies of cancer and one compound is currently approved by the FDA.



"Our biggest single emphasis the last few years has been Niemann-Pick among these rare diseases," Helquist said. "We developed several processes for the efficient preparation of these types of drugs. There's a stream of publications and also a stream of patents starting in June 2007 and continuing this year."



"If the results in human cells can be confirmed in clinical trials, the fact that the histone deacetylase inhibitors are already in advanced clinical trials or even approved drugs could greatly accelerate the development of a treatment for this devastating disease."


суббота, 17 сентября 2011 г.

Cholesterol and genes

Why does it seem like some people can eat all the ice cream they want without increasing their cholesterol or gaining much weight, while others with high cholesterol have to watch their diets like a hawk? Because no matter what their lifestyle, people's genes play an overriding role in their cholesterol response.


So says a new study by researchers at the Department of Energy's Lawrence Berkeley National Laboratory and the Children's Hospital Oakland Research Institute (CHORI), conducted by Paul Williams of Berkeley Lab's Life Sciences Division in collaboration with Robin Rawlings and Patricia Blanche of CHORI and Ronald M. Krauss of CHORI and Berkeley Lab's Genomics Division. They report their findings in the July 8, 2005, issue of the American Journal of Clinical Nutrition.


The investigators analyzed how "bad" cholesterol (low-density lipoprotein, or LDL, cholesterol) responded to diets that were either high or low in fat in 28 pairs of identical male twins - one twin a vigorous exerciser, the other a comparative couch potato.


"Although identical twins share exactly the same genes, we chose these twins because they had very different lifestyles," says Williams. "One member of each pair was a regular long-distance runner, someone we contacted through Runner's World magazine or at races around the country. His brother clocked 40 kilometers a week less, at least, if he exercised at all."


For six weeks the twins ate either a high-fat diet (40 percent of its calories from fat) or a low-fat diet (only 20 percent of its calories from fat); then the pairs switched diets for another six weeks. After each six-week period the twins' blood cholesterol levels were tested.


The researchers were interested in learning if blood cholesterol changes due to the different diets would be the same or different in each pair of genetically identical twins, even though their lifestyles were very different. A correlation of zero between the two would mean that their responses to the diets had no relation to each other, while a correlation of 1.0 would mean that their responses were identical.


The researchers found an astounding 0.7 correlation in responses to the change in diet, an incredibly strong similarity in the way each pair of twins responded - even though the responses themselves among different pairs of twins differed considerably.


"If one of the twins could eat a high-fat diet without increasing his bad cholesterol, then so could his brother," says Williams. "But if one of the twins' LDL cholesterol shot up when they went on the high-fat diet, his brother's did too."


The correlations showed that the twins had very similar changes in LDL cholesterol because they had the same genes. Some twins had one or more genes that made them very sensitive to the amount of fat in their diets. Other twins had genes that made them insensitive to dietary fat, no matter how much they exercised.


"Our experiment shows how important our genes are," says Williams. "Some people have to be careful about their diets, while others have much more freedom in their dietary choices."


He adds, "This type of experiment allows us to test whether genes are important without having to identify the specific genes involved." Although several specific genes have been associated with cholesterol changes in response to changes in diet, these cannot account for the large correlations seen in this study. Williams hopes his findings will inspire additional research to identify the specific genes involved.


"Concordant lipoprotein and weight responses to dietary fat change in identical twins with divergent exercise levels," by Paul T. Williams, Patricia J. Blanche, Robin Rawlings, and Ronald M. Krauss, appears in the July 8, 2005, issue of the American Journal of Clinical Nutrition. The work was supported by Dairy Management Incorporated, with additional support from the National Institutes of Health.


Berkeley Lab is a U.S. Department of Energy national laboratory located in Berkeley, California. It conducts unclassified scientific research and is managed by the University of California. Visit our website at

lbl.


Berkeley Lab News Release

среда, 14 сентября 2011 г.

QuatRx Pharmaceuticals Initiates Phase I Trial For Treatment To Reduce Both LDL Cholesterol And Lipoprotein (A)

QuatRx Pharmaceuticals, a privately held biopharmaceutical company focused on research and development of therapeutic compounds for the treatment of major endocrine,
metabolic and cardiovascular diseases, today announced that it has
initiated a Phase I clinical study of QRX-431, a novel compound in
development for the treatment of elevated cholesterol levels and obesity.


In pre-clinical primate studies, QRX-431, a selective thyroid beta agonist,
lowered LDL, lipoprotein (a) and weight without significantly increasing
heart rate. High levels of low-density lipoproteins (LDL) have been shown
to be a major cause of coronary heart disease, a condition affecting more
than 13 million Americans. Elevated lipoprotein (a) [Lp(a)] has been linked
to an increased risk of stroke and coronary heart disease.



"We are extremely encouraged by the preclinical results for QRX-431. We
feel this new drug candidate offers great promise as a therapy to help the
millions of people with elevated lipid levels and obesity who may be at
risk for stroke and coronary heart disease," said Robert L. Zerbe, M.D.,
chief executive officer and president of QuatRx.



Preclinical Study Results



In preclinical primate studies, QRX-431 significantly reduced LDL
cholesterol and Lp(a). To date, there are no approved therapies for the
treatment of elevated Lp(a) levels. Study results also suggest that QRX-431
activates reverse cholesterol transport, a protective mechanism involving
transport of cholesterol from the arteries to the liver. QRX-431 may also
act to induce weight loss. QRX-431 demonstrated a weight reduction in seven
days in a primate study and did not significantly affect heart rate.



LDL Cholesterol, Cardiovascular Disease and Current Treatments



Collectively, more than 71 million Americans have some form of
cardiovascular disease, according to the American Heart Association.
Cardiovascular disease is the number one killer in the United States,
claiming more lives than cancer, chronic lower respiratory diseases,
accidents, and diabetes combined. Statins are commonly used to lower LDL
cholesterol and reduce the risk of cardiovascular disease. Though effective
for many people with high LDL cholesterol, statins have no effect on Lp(a),
can cause many side effects and many people cannot tolerate the higher
doses needed to achieve target LDL levels. Thyroid hormone has been shown
to lower LDL levels and Lp(a), but unlike QRX-431, thyroid hormone also
stimulates the thyroid alpha receptor, which produces increases in heart
rate. For this reason, thyroid hormone has not been considered a viable
therapy for lowering cholesterol or weight.



About QuatRx



QuatRx Pharmaceuticals Company is focused on discovering, licensing,
developing and commercializing compounds in the endocrine, metabolic and
cardiovascular therapeutic areas. In addition to QRX-431, QuatRx currently
has three product candidates in clinical development. QuatRx's two lead
compounds target hormone deficiencies that result from aging in women and
men. Ophena(TM) is in Phase III development initially for the treatment of
vaginal atrophy, a common problem associated with estrogen deficiency in
post- menopausal women. Fispemifene, a treatment for testosterone
deficiency, is in Phase II clinical testing. QuatRx is also developing
Asord(TM), a topical product candidate for the treatment of psoriasis,
which has completed a Phase IIb clinical trial.


QuatRx Pharmaceuticals Company

quatrx

воскресенье, 11 сентября 2011 г.

Link Between Apolipoprotein E Genotypes With Lipid Levels And Coronary Risk

There are linear links between apolipoprotein E (apoE) genotypes with lipid levels and coronary risk, according to an analysis of previous studies published in the Journal of the American Medical Association (JAMA).


apoE, a multifunctional protein, plays a vital part in cholesterol and triglycerides metabolism, explain the writers. A number of studies have identified a link between some apoE genotypes and lipid levels and coronary risk. However, the majority of those studies were small and perhaps biased.


Anna M. Bennet, Ph.D., University of Cambridge, England, and team looked at a number of studies in order to see whether there was really a link between apoE with circulating lipid levels and coronary risk. There were 82 studies of lipid levels, involving 86,067 healthy subjects, and 121 studies of coronary outcomes - 37,850 cases and 82,727 controls - with a focus on studies with 1,000 healthy subjects or more for lipids and those with 500 or more coronary outcomes.


In the most extreme comparison, the scientists explained, individuals with the E2/E2 genotype had 31% lower average LDL-C (low-density lipoprotein cholesterol) values compared to people with the E4/E4 genotype. The authors wrote "??¦a difference comparable with that produced by 'statin' medication. The relationship of apoE genotypes with high-density lipoprotein cholesterol (HDL-C) was shallow and inverse and that with triglycerides was nonlinear and largely confined to the E2/E2 genotype, with the latter about 2 times weaker than previously reported."


The researchers added "We found that, in comparison with the commonest E3/E3 genotype, E2 carriers had a 20 percent reduced coronary risk, in contrast with previous estimates that E2 carriage is neutral for coronary risk. We noted strong evidence of selective publication in previous estimates based on smaller studies. This is a serious concern given that apoE genotypes and coronary risk had hitherto been considered among the few quantitatively secure associations in cardiovascular disease genetics."


E4 carriers have a slightly higher risk of coronary disease compared with E3/E3 individuals, the authors wrote.


JAMA. 2007;298(11):1300-1311

jama.ama-assn






четверг, 8 сентября 2011 г.

Most Americans do not know that high cholesterol comes from two sources

Results from a recent nationwide survey showed that most respondents did not know that high cholesterol comes from two sources, even though the respondents reported having high cholesterol. When asked about the sources of cholesterol, more than three-quarters of respondents (77 percent) stated incorrectly that the food they eat contributes the most to high cholesterol. In fact, the cholesterol in the bloodstream is not just absorbed from the food people eat, but the majority is produced naturally in the body.


Other findings from the survey showed that 45 percent of high cholesterol patients said they were more concerned about cholesterol compared to other personal health issues and 75 percent felt that their cholesterol should be lower.


"Patients with high cholesterol should make an extra effort to be as informed about their cholesterol levels as possible. Knowing about the sources of cholesterol is a key step in this process," says David Cohen, M.D., director of hepatology, Brigham and Women's Hospital. "The fact is that both diet and heredity play a critical role in your cholesterol levels. While diet can contribute significantly to elevated cholesterol, the body's natural chemistry can often produce dangerously high levels of LDL ("bad") cholesterol based on heredity alone. When working with a physician to manage your condition, it is important for patients to understand that there are two sources of cholesterol and in many cases both need to be addressed."


The survey results also showed:


Respondents did have a general sense that the lower their cholesterol the better; with 75 percent agreeing that their cholesterol should be lower than it currently is now.


Most respondents (85 percent) said they were aware there are national guidelines for where their overall cholesterol number should be. However, only 27 percent of those people actually knew that the optimal level for LDL cholesterol is less than 100mg/dL.


"The cholesterol awareness gap that is seen in this survey can and should be remedied," says Bonna Kol, executive director of Mended Hearts, a volunteer organization affiliated with the American Heart Association that provides supportive services to heart disease patients and their families nationwide. "High cholesterol is a serious condition, but it can be treated. Following a heart healthy diet, managing weight and staying physically active are essential lifestyle components we've encouraged for years. We've also emphasized the importance of informed patients talking with their doctor to ensure cholesterol goals are met. These findings reinforce that importance. Patients should work with their doctors on developing an approach to lowering cholesterol that is best for them."



The survey was sponsored by Merck/ Schering-Plough Pharmaceuticals in conjunction with Mended Hearts. The two organizations are developing educational materials and local awareness campaigns based on the findings to educate heart patients on the importance of reaching their cholesterol treatment goals.















About Cholesterol


Cholesterol is a form of fat or "lipid" found in the blood and all cells of the body. It is critically important in helping to form cell membranes, steroid hormones and bile acids. There are two sources of cholesterol: cholesterol comes from the food you eat and is produced naturally in the body. However, over time, excess LDL (or bad) cholesterol in the blood can build up on the inner walls of the arteries that supply blood to the heart. These deposits form plaque, which can cause the arteries to narrow, making them less efficient at transporting blood. This condition, called atherosclerosis, restricts blood flow, which can result in heart attack.


About the Survey


Merck/ Schering-Plough Pharmaceuticals, in partnership with Mended Hearts, sponsored the survey, which was conducted among 1,118 patients who reported having high cholesterol and who were members in a sub-panel of the Harris Interactive Chronic Illness Panel. This survey was composed of 566 respondents currently being treated with cholesterol lowering medicines and 552 currently untreated. The Harris Interactive Chronic Illness Panel(CIP) consists of over 1 million households where members have been screened for more than 50 separate medical conditions. The panel members are recruited from among Harris Interactive's general online consumer panel. The CIP allows targeted and effective sampling on specific populations of interest. Participants receive incentives for each survey they complete. Incentives are in the form of HI Points, which are ultimately redeemable for rewards (like pens, radios, and watches) at various point levels.


About Mended Hearts


Mended Hearts, a national nonprofit organization affiliated with the American Heart Association, has been offering the gift of hope to heart disease patients, their families and caregivers for more than 50 years. Recognized for its role in facilitating a positive patient-care experience, Mended Hearts partners with 460 hospitals and rehabilitation clinics and offers services to heart patients through visiting programs, support group meetings and educational forums. Its mission is to "inspire hope in heart disease patients and their families."


About Merck/Schering-Plough Pharmaceuticals


Merck/Schering-Plough Pharmaceuticals is a joint venture between Merck & Co., Inc. and Schering-Plough Corporation formed in May 2000 to develop and market in the United States new prescription medicines in cholesterol management. The collaboration was expanded in December 2001 to include worldwide markets (excluding Japan).


About Harris Interactive®


Harris Interactive (harrisinteractive) is a worldwide market research and consulting firm best known for The Harris Poll®, and for pioneering the Internet method to conduct scientifically accurate market research. Headquartered in Rochester, New York, Harris Interactive combines proprietary methodologies and technology with expertise in predictive, custom and strategic research. The Company conducts international research from its U.S. offices and through wholly owned subsidiaries--London-based HI Europe (hieurope), Paris-based Novatris and Tokyo-based Harris Interactive Japan--as well as through the Harris Interactive Global Network of independent market- and opinion-research firms.


For more information on cholesterol and its sources, please go to 2cholesterolsources.


Media Contacts:

Tim Elsner

214-706-1406

Mended Hearts


Kristin Francini

202-352-4806

Porter Novelli


Daphne Hoytt

212-601-8162

Porter Novelli

понедельник, 5 сентября 2011 г.

Metabolex Begins Phase 2 Trial Of MBX-8025 For Treatment Of Dyslipidemia

Metabolex, Inc., a
biotechnology company dedicated to the discovery and development of novel
therapeutics for diabetes and related metabolic disorders, announced
that it has begun a 180 patient Phase 2 trial of MBX-8025 in overweight or
obese patients with high cholesterol and triglycerides to assess the drug's
effect on dyslipidemia, insulin-resistance and obesity.


Preclinical and clinical testing of MBX-8025 indicates that the drug
has the potential to improve a number of lipid parameters that are abnormal
in different types of dyslipidemia, including high LDL (or "bad")
cholesterol, high Apo B-100 (the atherogenic lipoprotein), low HDL (or
"good") cholesterol and high triglycerides (fats). In addition, MBX-8025
has been shown to exhibit positive effects on insulin sensitization and
body weight. The randomized, double blind Phase 2 trial will assess the
potential of the drug alone and in combination with Lipitor(R)
(atorvastatin).



"Although high LDL levels are widely treated as a risk factor for heart
disease, many patients are unable to reach increasingly low LDL targets on
a statin alone. Additionally, existing drugs do a poor job of targeting the
entire range of different lipid disorders that contribute to cardiac risk.
We believe this trial will provide us crucial evidence in assessing the
ability of MBX-8025 to lower Apo B-100, LDL and triglyceride levels, as
well as raise HDL levels, improve insulin sensitivity and reduce body
weight," said David B. Karpf, M.D., the chief medical officer of Metabolex.
"In addition, we are testing the drug in conjunction with Lipitor, the
best-selling lipid-lowering drug in the world, to determine whether
combination therapy with a statin will be well tolerated and lead to even
better results."



The study will enroll 180 overweight or obese non diabetic patients and
assess two different doses of MBX-8025, given over an 8-week treatment
period, both alone and in combination with Lipitor(R). The primary endpoint
is the reduction in Apo B-100 compared with placebo. Secondary endpoints
include measurements of the effect of treatment on LDL, HDL, triglycerides
and body weight and composition. Metabolic parameters, including glucose
and insulin levels, will also be assessed.



MBX-8025 regulates fatty acid degradation, lipid storage/transport and
insulin sensitivity. Metabolex has in-licensed the patents and the
exclusive development and commercialization rights to MBX-8025 from Janssen
Pharmaceutica NV, a Johnson & Johnson company.



About Metabolex



Metabolex is a privately held biotechnology company dedicated to the
discovery and development of novel therapeutics to transform the treatment
of diabetes and related metabolic disorders. Metabolex has drawn on its
deep understanding of diabetes to create the largest database of genes
involved in diabetes and to build a rich pipeline of product candidates and
drug discovery targets. The company has three clinical-stage compounds:
MBX-102/JNJ 39659100, in Phase 2/3 testing; MBX-2044, in Phase 2a; and
MBX-8025, being studied in dyslipidemia, now in Phase 2. Ortho-McNeil, Inc.
has the exclusive right to develop and commercialize MBX-102/JNJ 39659100
and MBX-2044. For additional information about Metabolex and its
development pipeline, visit metabolex.


Metabolex, Inc.

metabolex

пятница, 2 сентября 2011 г.

Treat The Risk, Not The Cholesterol: Study Challenges Current Cholesterol Recommendations

A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better.


Tailoring treatment to a patient's overall heart attack risk, by considering all their risk factors, such as age, family history, and smoking status, was more effective, and used fewer high-dose statins, than current strategies to drive down cholesterol to a certain target, according to the U-M study.


While study authors support the use of cholesterol-lowering statins, they conclude that patients and their doctors should consider all the factors that put them at risk for heart attack and strokes.


The findings will be released online Monday ahead of print in the Annals of Internal Medicine.


"We've been worrying too much about people's cholesterol level and not enough about their overall risk of heart disease," says Rodney A. Hayward, M.D., director of the Veterans Affairs Center for Health Services Research and Development and a professor of internal medicine at the University of Michigan Medical School.


The National Cholesterol Education Program recommends harmful LDL cholesterol levels should be less than 130 for most people. High risk patients should be pushed even lower -- to less than 70.


The U-M study took a different approach, called tailored treatment, which uses a person's risk factors and mathematical models to calculate the expected benefit of treatment, by considering:


???A person's risk of a heart attack or stroke without treatment;

???How much a statin decreases the risk; and

???Potential harms from the treatment


"These are the three factors that determine the net benefit of a treatment. Our fixation on just one factor, LDL cholesterol, is leading us to often treat the wrong people," Hayward says.


In the recent study, U-M physicians who worked with Yale University School of Medicine used data from statin trials that included Americans ages 30-75 with no history of heart attack.


Study authors evaluated the benefit of five years of treatment that was tailored, on coronary artery disease risk factors such as age, family history, diabetes, high blood pressure, smoking status, and recently CRP, C-reactive protein.


The tailored approach was more efficient (more benefit per person treated) and prevented substantially more heart attacks, strokes and cardiovascular deaths than the currently recommended treat-to-target approaches.


The tailored strategy treated fewer individuals with high-dose statins and saved 500,000 more quality-adjusted life years.


"The bottom line message - knowing your overall heart attack risk is more important than knowing your cholesterol level," Hayward says. "If your overall risk is elevated, you should probably be on a statin regardless of what your cholesterol is and if your risk is very high, should probably be on a high dose of statin," the U-M physician says.


"However, if your LDL cholesterol is high, but your overall cardiac risk is low, taking a statin does not make sense for you," Hayward says. "If your cholesterol is your only risk factor and you're younger, you should work on diet and exercise."


Research has increasingly emerged questioning the value of cholesterol targets and which of statins mechanisms is most important to preventing cardiac events. Cholesterol-lowering drugs work by blocking a key enzyme linked with LDL cholesterol production, but they initiate other changes in the body.


"Statins also affect inflammation on the inside of our blood vessels which is often what causes heart attacks and strokes - it's not just a matter of cholesterol alone," he says.


Additional authors: Harlan M. Krumholz, M.D., Yale University School of Medicine, and Donna M. Zulman, M.D., Justin W. Timbie, Ph.D., and Sandeep Vijan, M.D, all of the VA Center for Health Services Research and Development, VA Ann Arbor Health Care System.


Funding: VA Health Services Research and Development Service's Quality Enhancement Research Initiative and the Measurement Core of the Michigan Diabetes Research & Training Center of the National Institutes of Health.


Source
University of Michigan Health System